Prescription Drugs

Efforts by CMS to reform the 340B Drug Pricing Program aim to decrease financial incentives that place revenue over patients' health outcomes and access to care.

The use of psychotropic medications in children is a complex issue for parents, caregivers, health care professionals, researchers, and policymakers. Psychotropic medications are used to treat behavioral health conditions. When these medications are prescribed appropriately, they can be effective in managing behavioral health symptoms.

We modeled the excess utilization of three commonly used drugs that treat heat-related illness in emergency departments during extreme heat events, using literature-derived estimates of emergency department visit rates for heat-related illness on extreme heat days and drug utilization rates from medical claims data.We estimate that extreme heat is associated with an average of 34,

Recent disruptions in medical product supply chains have highlighted the need for stronger, more coordinated approaches to ensuring reliable access to medical products.

Recent federal policy discussions have renewed focus on psychiatric medication use among children and adolescents. Psychiatric medications represent one evidence-based component within a spectrum of effective treatments for pediatric mental illness, alongside psychotherapy, family-based interventions, and school supports.

Older adults with behavioral health disorders often experience worse health and functional outcomes, have higher rates of emergency department visits, use more medications, and have higher health care costs than those without a behavioral health disorder. There is need for a greater understanding of the extent to which older adults experience behavioral health disorders.

The 2025-2028 Draft Action Plan for Addressing Shortages of Medical Products and Critical Foods and Strengthening the Resilience of Medical Product and Critical Food Supply Chains (“Draft Action Plan”) presents coordinated and strategic actions that the Department of Health and Human Services (“HHS,” or “Department”) plans to take from 2025 through 2028.

The U.S. has a number of policies related to drug pricing, affordability, and availability. To encourage manufacturers to innovate with new therapies, patent policy rewards the creation of new branded medicines. As those patents come to an end, generic drug manufacturers may enter a market and seek to sell their products at lower prices than the competing brand drugs.

The U.S. supply chain for provider-administered outpatient drugs involves several entities, including drug manufacturers, wholesalers, healthcare providers (e.g., outpatient facilities, hospital pharmacies, doctor’s offices, and standalone clinics), group purchasing organizations (GPOs), payers, and beneficiaries.